Intended for healthcare professionals

  1. Research
  2. Evidence b(i)ased...
  3. Evidence b(i)ased medicine—selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications
Papers

Evidence b(i)ased medicine—selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications

BMJ 2003; 326 doi: https://doi.org/10.1136/bmj.326.7400.1171 (Published 29 May 2003) Cite this as: BMJ 2003;326:1171

Related articles

See more

Cited by...

  • Englands new workforce plan is a propaganda masterclass in glossing over the gaps
  • Awareness and perceptions among members of a Japanese cancer patient advocacy group concerning the financial relationships between the pharmaceutical industry and physicians: a mixed-methods analysis of survey data
  • Suicide risk with selective serotonin reuptake inhibitors and other new-generation antidepressants in adults: a systematic review and meta-analysis of observational studies
  • Suicide risk with selective serotonin reuptake inhibitors and new-generation serotonergic-noradrenergic antidepressants in adults: a systematic review and meta-analysis of observational studies
  • Evidence of unexplained discrepancies between planned and conducted statistical analyses: a review of randomized trials
  • Reporting of drug trial funding sources and author financial conflicts of interest in Cochrane and non-Cochrane meta-analyses: a cross-sectional study
  • Prospective registration and reporting of trial number in randomised clinical trials: global cross sectional study of the adoption of ICMJE and Declaration of Helsinki recommendations
  • Assessing Confidence in the Results of Network Meta-Analysis (Cinema)
  • Research integrity and the law that never was
  • False Beliefs in Academic Psychiatry: The Case of Antidepressant Drugs
  • Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide
  • Reporting guidance considerations from a statistical perspective: overview of tools to enhance the rigour of reporting of randomised trials and systematic reviews
  • Cost-effectiveness research in cancer therapy: a systematic review of literature trends, methods and the influence of funding
  • Sponsorship bias in the comparative efficacy of psychotherapy and pharmacotherapy for adult depression: meta-analysis
  • Cross-sectional study of Pfizer-sponsored clinical trials: assessment of time to publication and publication history
  • How do authors of systematic reviews deal with research malpractice and misconduct in original studies? A cross-sectional analysis of systematic reviews and survey of their authors
  • Clinical trial registration, reporting, publication and FDAAA compliance: a cross-sectional analysis and ranking of new drugs approved by the FDA in 2012
  • Occurrence and determinants of selective reporting of clinical drug trials: design of an inception cohort study
  • Deviation from intention to treat analysis in randomised trials and treatment effect estimates: meta-epidemiological study
  • The Chemical Imbalance Hypothesis: An Evaluation of the Evidence
  • Industry sponsorship bias in research findings: a network meta-analysis of LDL cholesterol reduction in randomised trials of statins
  • Differences in reporting serious adverse events in industry sponsored clinical trial registries and journal articles on antidepressant and antipsychotic drugs: a cross-sectional study
  • Benefits and harms in clinical trials of duloxetine for treatment of major depressive disorder: comparison of clinical study reports, trial registries, and publications
  • Clinical study reports of randomised controlled trials: an exploratory review of previously confidential industry reports
  • "Hardly worth the effort"? Medical journals' policies and their editors' and publishers' views on trial registration and publication bias: quantitative and qualitative study
  • Restoring invisible and abandoned trials: a call for people to publish the findings
  • Effectiveness of non-benzodiazepine hypnotics in treatment of adult insomnia: meta-analysis of data submitted to the Food and Drug Administration
  • Reporting of conflicts of interest from drug trials in Cochrane reviews: cross sectional study
  • Second-generation antidepressants
  • Misinformation in the medical literature: What role do error and fraud play?
  • Opening up data at the European Medicines Agency
  • Effect of reporting bias on meta-analyses of drug trials: reanalysis of meta-analyses
  • Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials
  • Modified intention to treat reporting in randomised controlled trials: systematic review
  • Europe's opportunity to open up drug regulation
  • CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials
  • Missing published and unpublished data in guidelines
  • The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration
  • Making the best use of available evidence: the case of new generation antidepressants: A response to: Are all antidepressants equal?
  • The effects of excluding patients from the analysis in randomised controlled trials: meta-epidemiological study
  • How to increase the value of randomised trials in COPD research
  • Novel methods to deal with publication biases: secondary analysis of antidepressant trials in the FDA trial registry database and related journal publications
  • Accounting for uncertainty about investigator bias: disclosure is informative: How could disclosure of interests work better in medicine, epidemiology and public health?
  • Build bridges with the drugs industry--but keep patients in mind
  • Discrepancies in sample size calculations and data analyses reported in randomised trials: comparison of publications with protocols
  • Evaluating solutions to sponsorship bias
  • Management of depression in adults
  • Child psychiatry and its relationship with the pharmaceutical industry: theoretical and practical issues
  • Putting evidence into context: some advice for guideline writers
  • Putting evidence into context: some advice for guideline writers
  • Frequency, Type, and Monetary Value of Financial Conflicts of Interest in Cancer Clinical Research
  • Clinical trial registration at Tobacco Control
  • Merits of psychotherapies.
  • Disentangling The Web
  • AMODIAQUINE AND COMBINATION CHEMOTHERAPY FOR MALARIA
  • Efficacy of antidepressants in adults
  • The influence of big pharma
  • Psychiatry and the pharmaceutical industry: who pays the piper?: A perspective from the Critical Psychiatry Network
  • When Health Policy Is the Problem: A Report from the Field
  • Transparency in drug regulation: Mirage or oasis?
  • Outcome reporting bias in randomized trials funded by the Canadian Institutes of Health Research
  • Evidence-Based Pandemonium
  • Good practice in publication of clinical trial results
  • Risk of suicide remains high fifteen years after deliberate self-harm
  • Bias in Pharmaceutical-Sponsored Research?
  • Bias in Pharmaceutical-Sponsored Research?
  • No more free lunches
Back to top